L'Oréal: H1 results in line with expectations, but Western Europe disapoints
L'Oréal: (BUY, Fair Value EUR206 (-2%))H1 results in line with expectations, but Western Europe disapoints
Half year results of L’Oréal were bang in line with market expectations both at top line than at EBIT line. Sales grew 6.6% in H1 with +6.3% in Q2 vs +6.7% in Q1. EBIT margin improved 30bp to 19.2%, mainly driven by gross margin. Buy recommendation maintained.
L'Oreal acts as a holding company. Through its subsidiaries, Co. plays a strategic coordination role and scientific, industrial and marketing coordination role on a global basis. Co. develops, manufactures and commercializes products for Skin care, Hair care, Make-up, Perfumes, Toiletries and deodorants, and Oral cosmetics. Co. has three branches: Cosmetics, Body shop and Dermatology. Co.'s principal activities comprise four divisions: Professional Products, Consumer Products, L'Oreal Luxe and Active Cosmetics. The Body Shop branch offers various cosmetics and toiletry products. The Dermatology branch offers topical dermatology prescription, and corrective and aesthetic dermatology.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.